Navigation Links
American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
Date:2/3/2011

SHIRLEY, N.Y., Feb. 3, 2011 /PRNewswire/ -- American Regent is conducting a nationwide voluntary recall to the consumer and user level of the following product:Potassium PhoshaesInjection,USP,15mM/5 mLPhoshorus;22mEq/5mLoassium5mLSingleDoseVialNDC# 0517-2305-25Lot # 0048ExpDate:  January,2012PLEASE NOTE:  This recall, initiated on February 3, 2011 to the User or Consumer Level, is for lot # 0048 Only.  No other lots or sizes of Potassium Phosphates Injection, USP are subject to this voluntary recall.This voluntary recall was initiated because some vials of this lot exhibit translucent visible particles consistent with glass delamination.

Potential adverse events after intravenous administration include damage to blood vessels in the lung, localized swelling, and granuloma formation.  American Regent is undertaking this recall in consideration of the potential for safety issues if this lot of product is administered to patients.

Potassium Phosphates Injection, USP, 3 mM Phosphorus/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

The product was distributed to wholesalers and distributors nationwide.

Hospitals, Home Health Care Agencies, Emergency Rooms, Infusion Centers, Clinics and other healthcare facilities should not use American Regent, Inc., Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, with lot # 0048 for patient care and should immediately quarantine any product for return.

American Regent is notifying its distributors and consumers by email, facsimile and/or overnight courier and is arranging for return of all recalled product.  Consumers/distributors/retailers that have product which is being recalled should stop use.

AmericanRegentwill creditaccountsfoall eturned producwith this lot#. Thosewith questionsabout thereturnor ecallprocess, pleasecall our CustomeServiceDepartmenat 1-877-788-3232: Monday thu Friday fom8:30AMto7:00PMEST.Hositals, Home Health Agencies, Emegency ooms, Infusion Centers, Clinics and Healthcare Providers,or patients withproduct quality complains, medicalor ohequestions concerning the useof he product or reasons for his recall should contact the Pofessional SevicesDepartmena1-877-788-3232.Anyadvese reactions experiencedwiththe use of this poduct should be reported to AmericanRegent,Inc.viaemailat pv@luitpold.combyfaxo (610)650-7781or (610)650-0170oryhonea1-800-734-9236.  TOEXPEDITE HANDLINGPLEASE DONOT REPO ANYTHINGOTHETHANSPECIFIC ADVERSE EVENTS TO THIS EMAIL ADDRESS OR FAX O PHONE.Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or regular mail or by fax.

  • Online: www.fda.gov/medwatch/report.htm
  • Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.
  • Fax: 1-800-FDA-0178

  • "All of us at American Regent and Luitpold are taking the necessary steps to protect patients from any potential safety risks with our Potassium Phosphates Injection. The safety and well being of patients receiving our products is our primary concern," said Mary Jane Helenek, President and CEO of American Regent.

    While American Regent continues to investigate this issue, the company is taking precautionary action and initiated this voluntary recall.  American Regent has informed the FDA of its actions and is maintaining ongoing discussions with the agency.

    As is standard practice, and as stated in the Potassium Phosphates Injection, USP, Product Package Insert, "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."

    Potassium Phosphates Injection, USP is manufactured by Luitpold Pharmaceuticals, Inc. and is distributed by American Regent, Inc. (Shirley, NY).

    Source: Luitpold Pharmaceuticals, Inc.

    This voluntary recall is being conducted with the knowledge of the U.S. Food and Drug Administration.


    '/>"/>

    SOURCE Luitpold Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. American Regent Initiates Nationwide Voluntary Recall of Sodium Thiosulfate Injection, USP
    2. Surgical Information Systems Completes IHE North American Connectathon
    3. American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
    4. American Oriental Bioengineerings CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintaos Delegation
    5. Maldonado Medicals Green Initiative, a Model for the American Small Business
    6. American Medical Systems Launches STEP Patient Education Program in Europe
    7. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
    8. Amarin Announces Successful Completion of Offering of American Depositary Shares
    9. Amarin Prices Public Offering of American Depositary Shares
    10. Pharmacists Encourage Americans to Consider Medicine Cabinet Cleanout Among New Years Resolutions
    11. CVS CAREMARK to Purchase Universal Americans Medicare Part D Business
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
    (Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
    (Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
    Breaking Medicine Technology:
    (Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
    (Date:8/16/2017)... ... , ... “God Will Break Every Chain”: an inspirational story for those shackled by the chains ... author, Evangelist Joann Shivers, a writer and a woman of great faith and wisdom. ... early age. She was born and raised in Vero Beach, Florida and has dedicated ...
    (Date:8/15/2017)... ... August 15, 2017 , ... The first study to ... multiple myeloma has been completed, with the team’s findings now published online ahead of ... , Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, ...
    (Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
    (Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis ... periodontal disease . This information can be used to develop patient-specific treatment ... The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® ...
    Breaking Medicine News(10 mins):